BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30550588)

  • 1. Geo-spatial analysis of individual-level needle and syringe coverage in Melbourne, Australia.
    O'Keefe D; Wilkinson A; Aitken C; Dietze P
    PLoS One; 2018; 13(12):e0209280. PubMed ID: 30550588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of time of drug use according to needle and syringe program operating hours in Melbourne, Australia: Effects on individual-level needle and syringe coverage.
    O'Keefe D; Aitken C; Scott N; Dietze P
    Drug Alcohol Depend; 2018 Oct; 191():259-265. PubMed ID: 30153607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal analysis of change in individual-level needle and syringe coverage amongst a cohort of people who inject drugs in Melbourne, Australia.
    O'Keefe D; Scott N; Aitken C; Dietze P
    Drug Alcohol Depend; 2017 Jul; 176():7-13. PubMed ID: 28463684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on syringe coverage and service uptake among needle and syringe programs in the United States, 2019-2020.
    Tookes HE; Bartholomew TS; Sugar SES; Plesons MD; Bluthenthal RN; Wenger LD; Patel SV; Kral AH; Lambdin BH
    Int J Drug Policy; 2024 Jan; 123():104289. PubMed ID: 38071932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "No-one just does drugs during business hours!": evaluation of a 24/7 primary needle and syringe program in St Kilda, Australia.
    Walker S; Curtis M; Kirwan A; Thatcher R; Dietze P
    Harm Reduct J; 2024 Feb; 21(1):51. PubMed ID: 38402389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-series analysis of presentations to four syringe dispensing machines and a needle and syringe programme during COVID-19 lockdowns in Melbourne, Australia.
    O'Keefe D; Livingston M; Cossar RD; Kerr P; Jacka D; Dietze P
    Harm Reduct J; 2022 Sep; 19(1):101. PubMed ID: 36071500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of four syringe dispensing machine point-of-access data 2017-2020 in Melbourne, Australia: machine utilisation and client demographics.
    Kerr P; Cossar RD; Livingston M; Jacka D; Dietze P; O'Keefe D
    Harm Reduct J; 2022 Dec; 19(1):144. PubMed ID: 36544124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis.
    O'Keefe D; Scott N; Aitken C; Dietze P
    BMC Health Serv Res; 2016 Aug; 16(1):411. PubMed ID: 27542604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual-level syringe coverage among Needle and Syringe Program attendees in Australia.
    Iversen J; Topp L; Wand H; Maher L
    Drug Alcohol Depend; 2012 May; 122(3):195-200. PubMed ID: 22071120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syringe Stockpiling by Persons Who Inject Drugs: An Evaluation of Current Measures for Needle and Syringe Program Coverage.
    McCormack AR; Aitken CK; Burns LA; Cogger S; Dietze PM
    Am J Epidemiol; 2016 May; 183(9):852-60. PubMed ID: 27049004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of needle and syringe program services in the Kyrgyz Republic: Key barriers and facilitators.
    Deryabina A; El-Sadr WM
    Drug Alcohol Depend; 2017 Oct; 179():180-186. PubMed ID: 28787695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016.
    Kwon JA; Iversen J; Law M; Dolan K; Wand H; Maher L
    Drug Alcohol Depend; 2019 Apr; 197():108-114. PubMed ID: 30802734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Needle and syringe distribution trends in Western Australia, 1990 to 2009.
    Lilley G; Mak DB; Fredericks T
    Drug Alcohol Rev; 2013 May; 32(3):320-7. PubMed ID: 22963615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do needle and syringe programs reduce risky behaviours among people who inject drugs in Kermanshah City, Iran? A coarsened exact matching approach.
    Noroozi M; Marshall BDL; Noroozi A; Armoon B; Sharifi H; Farhoudian A; Ghiasvand H; Vameghi M; Rezaei O; Sayadnasiri M; Pouya RH
    Drug Alcohol Rev; 2018 Apr; 37 Suppl 1():S303-S308. PubMed ID: 29271013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there differences in individual-level needle and syringe coverage across Australian jurisdictions related to program policy? A preliminary analysis.
    Hill P; O'Keefe D; Dietze PM
    Drug Alcohol Rev; 2018 Jul; 37(5):653-657. PubMed ID: 29851167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran.
    Nazari SS; Noroozi M; Soori H; Noroozi A; Mehrabi Y; Hajebi A; Sharifi H; Higgs P; Mirzazadeh A
    Int J Drug Policy; 2016 Jan; 27():127-31. PubMed ID: 26764125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis.
    Sawangjit R; Khan TM; Chaiyakunapruk N
    Addiction; 2017 Feb; 112(2):236-247. PubMed ID: 27566970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs.
    Treloar C; Rance J; Yates K; Mao L
    Int J Drug Policy; 2016 Jan; 27():138-45. PubMed ID: 26394538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.